NCT03056755
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: Tumor must harbor PIK3CA mutation
Exclusions: Unstable central nervous system (CNS) involvement- see trial for details
https://ClinicalTrials.gov/show/NCT03056755